Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentonium is a synthetic small molecule drug classified as an atropine derivative and a quaternary analog of hyoscyamine. It acts primarily as an anticholinergic, antispasmodic, and anti-ulcerogenic agent. Fentonium functions by blocking muscarinic acetylcholine receptors (antimuscarinic action), thereby inhibiting parasympathetic nerve impulses in smooth muscle, secretory glands, and the central nervous system. Additionally, it is reported to act as an allosteric blocker of α12βγε nicotinic receptors and can increase spontaneous acetylcholine release at the motor endplate without depolarizing muscle or inhibiting cholinesterase activity. Fentonium has been investigated for its effects on gastrointestinal disorders and opioid withdrawal symptoms in animal models[1][2][5][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentonium.